CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ANEMIA

Abstract

Anemia is one of the manifestations of systemic inflammation in chronic obstructive pulmonary disease (COPD) and is a factor aggravating the course of the disease. Objective. To study gender peculiarities of anemia in COPD patients, to increase the effectiveness of treatment by using pharmacological preparations of erythropoietin and enteral iron. Material and methods. Clinical data of examination of 74 patients with COPD II and III stages with anemia and the results of treatment of 49 patients who received pharmacological preparations of erythropoietin and enteric iron are presented and treatment results of 49 patients who received epoetin and sorbifer durules in addition to standard therapy. Results. In COPD patients with anemia iron deficiency anemia was statistically significantly more frequent - in 63 (85,1%): in 39 (61,9%) women and 24 (38,1%) men. In 11 (14.9%) patients, normocytic anemia having parameters of anemia of chronic diseases. The frequency of iron deficiency anemia in patients of both sexes correlated with age and was predominantly moderately severe; the moderate degree of severity was statistically more often confirmed in women - 24 (61.5%) out of 39 patients, in men the predominance of the mild variant of iron deficiency - 14 (58.3%) out of 24 patients. Conclusion. The prevalence of concomitant anemia in COPD was 26.5%; anemia was verified in 44 (33.7%) women, i.e. in every third patient, in men anemia was significantly less frequent - in 30 (20, 7%) patients. The presence of anemia significantly worsens the condition of patients, especially female patients, who are more concerned with dyspnea, impairment of well-being, fatigue, depression, and they need more frequent hospitalizations. Correction of anemia by erythropoietin and enteral iron preparations makes it possible to increase physical endurance of patients, reduce the intensity of cough, dyspnea and maintain positive dynamics of physical tolerance for a long time after completion of the course of antianemic therapy.